Second Laparoscopic Surgery for Recurrent Unilateral Endometriomas.

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Status

Completed

Conditions

Surgery

Endometriosis

Endometrioma

Treatments

Other: Follicle-stimulating hormone (FSH) level dosage.

Other: Anti-mullerian hormone (AMH) level dosage.

Other: Antral follicle count (AFC).

Study type

Observational

Funder types

Other

Identifiers

NCT02047838

Lillo 01/2014

Details and patient eligibility

About

This retrospective case-control study was performed in an Academic centre for the diagnosis and treatment of endometriosis. It included patients with recurrent unilateral endometriomas who were previously operated for the same condition (cases) and patients without recurrency who previously underwent surgery for unilateral endometrioma (controls). The primary outcome of the study was to assess the impact on ovarian reserve of second surgery for recurrent unilateral endometriomas. The evaluation of ovarian reserve was performed by assessing serum anti-mullerian hormone (AMH) level, serum follicle-stimulating hormone (FSH) level, 17-beta estradiol level and antral follicle count (AFC).

Enrollment

36 patients

Sex

Female

Ages

18 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

reproductive age (at the time of both surgical procedures);
two surgical procedures on the same ovary (stripping of endometrioma with
largest diameter ≥ 4 cm; cases) performed at our Institution;
one surgical procedures (stripping of endometrioma with largest diameter ≥ 4 cm; controls) performed at our Institution;
histological diagnosis of ovarian endometriomas;
complete assessment of ovarian reserve at routinary follow-up at our institution.

Exclusion criteria

patients aged ≥ 40 years at the time of primary surgery;
surgical procedures on the contralateral ovary (at primary or second-line surgery);
previous salpingectomy or hysterectomy;
unilateral ovariectomy at the time of first or second surgery;
ultrasonographic diagnosis of persistent endometrioma after first surgery;
additional surgical procedures for endometriomas or for other ovarian diseases before first surgery and between first and second surgery;
hormonal treatment within 3 months from ovarian reserve assessment;
patients followed-up < 3 months after second-line surgery (for cases).
pregnancy and/or breastfeeding during the study period.